Lampalizumab

Lampalizumab (RG 7417) is a humanised monoclonal antibody targeting complement Factor D in the alternative complement pathway. Lampalizumab binds an exosite and sterically blocks Factor B access to the active site. Lampalizumab can be used for age-related macular degeneration (AMD) research[1][2].

Product Specifications

CAS Number

[1278466-20-8]

Product Name Alternative

RG 7417; TNX 234; Anti-CFD Recombinant Antibody

UNSPSC

12352203

Target

Complement System

Type

Inhibitory Antibodies

Related Pathways

Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/lampalizumab.html

Purity

99.46

Solubility

H2O

Smiles

[Lampalizumab]

Molecular Weight

(143.8 kDa)

References & Citations

[1]Yuan X, et al. Small-molecule factor D inhibitors selectively block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. Haematologica. 2017 Mar;102 (3) :466-475.|[2]Hanus J, et al. Current therapeutic developments in atrophic age-related macular degeneration. Br J Ophthalmol. 2016 Jan;100 (1) :122-7.